How Long Does Gene Editing Last?
May 17, 2022 | Terry Sharrer
“. . . Intellia [Cambridge, MA] is presenting additional data from the phase 1 trial for NTLA-2001 in transthyretin, or ATTR, amyloidosis. . . . The company is filling in some pieces that were missing when initial data in June 2021 showed the CRISPR gene editing therapy significantly reduced a known biomarker of the disease. Intellia has confirmed in interim data that the reduction in serum levels of transthyretin, or TTR, was maintained in patients after follow-up that ranged from two months to 12 months post-treatment. The company also said NTLA-2001 spurred a greater reduction in serum with a higher dose.” MORE
Image Credit: FierceBiotech.com